Copka Sonpashan

Copka Sonpashan is a clinical-stage healthcare and research entity focused on the development and evaluation of therapeutic interventions for neurological, respiratory, and rehabilitation-related conditions. The company serves as a lead sponsor for a diverse range of clinical trials investigating treatments for dysphagia, traumatic brain injury, Parkinson's disease, and obstructive sleep apnea. Its research portfolio highlights innovative applications of established modalities, such as stellate ganglion blocks using lidocaine, as well as behavioral interventions like diaphragm training and myofascial release therapy. Copka Sonpashan collaborates with prominent medical institutions, including Chao Phya Abhaibhubejhr Hospital in Thailand and Zhengzhou University in China, to advance clinical evidence for its programs. The company's work primarily targets improving the quality of life and functional outcomes for patients with complex chronic conditions.